Mediwound announces a 1-for-7 reverse share split

Yavne, israel, dec. 05, 2022 (globe newswire) -- mediwound ltd. (nasdaq: mdwd) (“mediwound” or the “company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it intends to effect a 1-for-7 reverse share split of its ordinary shares. subject to the company's satisfaction of nasdaq operations notice requirements, the scheduled effective date is december 20, 2022, with trading on a reverse split-adjusted basis to begin at market open on that day. trading of the company's ordinary shares will continue on the nasdaq global market under the symbol “mdwd,” but the shares will trade under the new cusip number, m68830112. in the event of a delay in the effective date, the company will update the public via a subsequent press release.
MDWD Ratings Summary
MDWD Quant Ranking